Estamos no ar no ! Saiba mais
ícone de RPRX

Royalty Pharma
RPRX

60,96 USD
+1,34
2,25%
No fechamento Atualizado 16 de out. 16:00 EDT
Pré-mercado
Após o fechamento do mercado
60,96
0,00
0%
1 dia
2,25%
5 dias
6,87%
1 mês
4,26%
3 meses
4,15%
6 meses
25,74%
No acumulado do ano
56,87%
1 ano
67,75%
5 anos
64,67%
10 anos
36,99%
 

Sobre: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Funcionários: 100

Saúde Biotecnologia

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 48,3%
Neutro 48,3%
Negativo 3,4%
Neutro
GlobeNewsWire
há 20 horas
Royalty Pharma declares fourth quarter 2026 dividend
NEW YORK, Oct. 16, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2026 of $0.235 per Class A ordinary share.
Royalty Pharma declares fourth quarter 2026 dividend
Neutro
GlobeNewsWire
há 7 dias
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Positivo
Zacks Investment Research
há 8 dias
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again
Positivo
The Motley Fool
há 15 dias
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Royalty Pharma offers exposure to a diversified portfolio of promising drug products and candidates. Its approach provides an optimal way to gain exposure to solid returns with minimal downside risk.
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?
Positivo
MarketBeat
há 22 dias
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
Royalty Pharma NASDAQ: RPRX executives said the company is monitoring a shifting biopharma policy environment, expanding its artificial-intelligence capabilities and building a presence in China, while maintaining a disciplined approach to capital deployment and leverage.
Royalty Pharma Eyes AI, China Growth While Navigating Biopharma Policy Shifts
Positivo
The Motley Fool
há 22 dias
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Revolution Medicines has just received good news around a drug meant to treat pancreatic cancer. While the company has multiple drugs in development, buying Revolution Medicines is still basically like putting all of your eggs in one basket.
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Neutro
Seeking Alpha
há 23 dias
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutro
GlobeNewsWire
mês passado
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
NEW YORK and WASHINGTON, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma and Blood Cancer United today announced a $7.5 million donation from Royalty Pharma to support Blood Cancer United's Therapy Acceleration Program (TAP), a collaborative venture philanthropy initiative designed to accelerate the development of promising blood cancer therapies through strategic equity investments and hands-on collaboration with biotech companies.
Royalty Pharma announces $7.5 million gift to Blood Cancer United to expand Therapy Acceleration Program
Neutro
Seeking Alpha
mês passado
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Royalty Pharma plc (RPRX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Neutro
GlobeNewsWire
mês passado
Royalty Pharma to present at upcoming investor conferences
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September:
Royalty Pharma to present at upcoming investor conferences
Ver ranking de notícias
Gráficos de preços implementados com Lightweight Charts™